Literature DB >> 17470544

Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron.

Anatoly Slepenkin1, Per-Anders Enquist, Ulrik Hägglund, Luis M de la Maza, Mikael Elofsson, Ellena M Peterson.   

Abstract

INPs, which are chemically synthesized compounds belonging to a class of acylated hydrazones of salicylaldehydes, can inhibit the growth of Chlamydiaceae. Evidence has been presented that in Yersinia and Chlamydia INPs may affect the type III secretion (T3S) system. In the present study 25 INPs were screened for antichlamydial activity at a concentration of 50 muM, and 14 were able to completely inhibit the growth of Chlamydia trachomatis serovar D in McCoy and HeLa 229 cells. The antichlamydial activities of two of these INPs, INPs 0341 and 0400, were further characterized due to their low cytotoxicity. These compounds were found to inhibit C. trachomatis in a dose-dependent manner; were not toxic to elementary bodies; were cidal at a concentration of > or =20 microM; inhibited all Chlamydiaceae tested; and could inhibit the development of C. trachomatis as determined by the yield of progeny when they were added up to 24 h postinfection. INP 0341 was able to affect the expression of several T3S genes. Compared to the expression in control cultures, lcrH-1, copB, and incA, all middle- to late-expressed T3S genes, were not expressed in the INP 0341-treated cultures 24 to 36 h postinfection. Iron, supplied as ferrous sulfate, as ferric chloride, or as holo-transferrin, was able to negate the antichlamydial properties of the INPs. In contrast, apo-transferrin and other divalent metal ions tested were not able to reverse the inhibitory effect of the INPs. In conclusion, the potent antichlamydial activity of INPs is directly or indirectly linked with iron, and this inhibition of Chlamydia has an effect on the T3S system of this intracellular pathogen.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17470544      PMCID: PMC1932962          DOI: 10.1128/IAI.00023-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  Type III secretion system in Chlamydia species: identified members and candidates.

Authors:  A Subtil; A Blocker; A Dautry-Varsat
Journal:  Microbes Infect       Date:  2000-04       Impact factor: 2.700

2.  Analysis of putative Chlamydia trachomatis chaperones Scc2 and Scc3 and their use in the identification of type III secretion substrates.

Authors:  Kenneth A Fields; Elizabeth R Fischer; David J Mead; Ted Hackstadt
Journal:  J Bacteriol       Date:  2005-09       Impact factor: 3.490

3.  A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis.

Authors:  Sandra Muschiol; Leslie Bailey; Asa Gylfe; Charlotta Sundin; Kjell Hultenby; Sven Bergström; Mikael Elofsson; Hans Wolf-Watz; Staffan Normark; Birgitta Henriques-Normark
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-14       Impact factor: 11.205

4.  Small-molecule inhibitors specifically targeting type III secretion.

Authors:  R Nordfelth; A M Kauppi; H A Norberg; H Wolf-Watz; M Elofsson
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

5.  Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle.

Authors:  Leslie Bailey; Asa Gylfe; Charlotta Sundin; Sandra Muschiol; Mikael Elofsson; Peter Nordström; Birgitta Henriques-Normark; Raimond Lugert; Anders Waldenström; Hans Wolf-Watz; Sven Bergström
Journal:  FEBS Lett       Date:  2007-01-17       Impact factor: 4.124

6.  Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle.

Authors:  K Wolf; H J Betts; B Chellas-Géry; S Hower; C N Linton; K A Fields
Journal:  Mol Microbiol       Date:  2006-09       Impact factor: 3.501

Review 7.  The evolution of iron chelators for the treatment of iron overload disease and cancer.

Authors:  Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2005-12       Impact factor: 25.468

8.  Mobilization of iron from cells by hydroxyquinoline-based chelators.

Authors:  C Mouralian; J L Buss; B Stranix; J Chin; P Ponka
Journal:  Biochem Pharmacol       Date:  2005-11-28       Impact factor: 5.858

9.  Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis.

Authors:  R S Stephens; S Kalman; C Lammel; J Fan; R Marathe; L Aravind; W Mitchell; L Olinger; R L Tatusov; Q Zhao; E V Koonin; R W Davis
Journal:  Science       Date:  1998-10-23       Impact factor: 47.728

10.  Ultrastructural analysis of the growth cycle of Chlamydia trachomatis in mouse cells treated with recombinant human alpha-interferons.

Authors:  L M de la Maza; J M Goebel; C W Czarniecki; E M Peterson
Journal:  Exp Mol Pathol       Date:  1984-10       Impact factor: 3.362

View more
  42 in total

1.  Protection of mice from a Chlamydia trachomatis vaginal infection using a Salicylidene acylhydrazide, a potential microbicide.

Authors:  Anatoly Slepenkin; Hencelyn Chu; Mikael Elofsson; Pia Keyser; Ellena M Peterson
Journal:  J Infect Dis       Date:  2011-09-20       Impact factor: 5.226

2.  Promoters for Chlamydia type III secretion genes show a differential response to DNA supercoiling that correlates with temporal expression pattern.

Authors:  Elizabeth Di Russo Case; Ellena M Peterson; Ming Tan
Journal:  J Bacteriol       Date:  2010-03-16       Impact factor: 3.490

3.  Characterization of the effects of salicylidene acylhydrazide compounds on type III secretion in Escherichia coli O157:H7.

Authors:  Jai J Tree; Dai Wang; Carol McInally; Arvind Mahajan; Abigail Layton; Irene Houghton; Mikael Elofsson; Mark P Stevens; David L Gally; Andrew J Roe
Journal:  Infect Immun       Date:  2009-07-27       Impact factor: 3.441

4.  Inflammasome-dependent caspase-1 activation in cervical epithelial cells stimulates growth of the intracellular pathogen Chlamydia trachomatis.

Authors:  Ali A Abdul-Sater; Evonne Koo; Georg Häcker; David M Ojcius
Journal:  J Biol Chem       Date:  2009-07-31       Impact factor: 5.157

5.  Analysis of Chlamydia pneumoniae infection in mononuclear cells by reverse transcription-PCR targeted to chlamydial gene transcripts.

Authors:  Laura Mannonen; Eveliina Markkula; Mirja Puolakkainen
Journal:  Med Microbiol Immunol       Date:  2011-01-30       Impact factor: 3.402

6.  Chlamydia trachomatis secretion of hypothetical protein CT622 into host cell cytoplasm via a secretion pathway that can be inhibited by the type III secretion system inhibitor compound 1.

Authors:  Siqi Gong; Lei Lei; Xiaotong Chang; Robert Belland; Guangming Zhong
Journal:  Microbiology (Reading)       Date:  2011-01-13       Impact factor: 2.777

7.  Cytosporone B, an inhibitor of the type III secretion system of Salmonella enterica serovar Typhimurium.

Authors:  Jianfang Li; Chao Lv; Weiyang Sun; Zhenyu Li; Xiaowei Han; Yaoyao Li; Yuemao Shen
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

Review 8.  Promises and Challenges of the Type Three Secretion System Injectisome as an Antivirulence Target.

Authors:  Alyssa C Fasciano; Lamyaa Shaban; Joan Mecsas
Journal:  EcoSal Plus       Date:  2019-02

9.  Haptoglobin and sickle cell polymorphisms and risk of active trachoma in Gambian children.

Authors:  Mathilde Savy; Branwen J Hennig; Conor P Doherty; Anthony J Fulford; Robin Bailey; Martin J Holland; Giorgio Sirugo; Kirk A Rockett; Dominic P Kwiatkowski; Andrew M Prentice; Sharon E Cox
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

10.  Small molecule inhibitors of the Yersinia type III secretion system impair the development of Chlamydia after entry into host cells.

Authors:  Sandra Muschiol; Staffan Normark; Birgitta Henriques-Normark; Agathe Subtil
Journal:  BMC Microbiol       Date:  2009-04-21       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.